This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Nicholas Z. Kerin, MD; Roger D. Blevins, PharmD; Lary Goldman, MD; Kathy Faitel, RN; Melvyn Rubenfire, MD

Arch Intern Med. 1988;148(8):1779-1781.

Abstract
• Eight patients concurrently treated with amiodarone and warfarin sodium were studied to characterize the interaction between these drugs. All fulfilled the following criteria: (1) stable and therapeutic prothrombin time (PT) at baseline, defined as at least two consecutive PTs obtained within two weeks before beginning amiodarone therapy that varied by 15%; (2) no warfarin dosage adjustment in the two weeks prior to amiodarone therapy; (3) no other drugs given that alter coagulation study results; and (4) follow-up PTs obtained 1, 2, 4, and 8 weeks after initiation of amiodarone treatment. A clinically significant change in PT was defined as >15%. Mean baseline PT was 19.8 s for patients receiving 5.99 mg/d of warfarin sodium. Patients had a mean maximum increase In PT of 44% (range, 22% to 108%), which occurred during the first two weeks. In six patients, the PT returned to within 15% of baseline by week 4 or 8, and the daily warfarin requirement had decreased by 35% (range, 25% to 50%). Two patients had PTs varying by >15% from baseline at week 8 despite a 33% reduction in warfarin dosage in each case. No patient In this series encountered complications of anticoagulant therapy, perhaps due to early recognition and dosage reduction. Although the mechanism remains unclear, our study indicates that amiodarone potentiation of warfarin effects occurs in all patients, occurs in the first two weeks of amiodarone therapy, variably increases PT by 22% to 108%, and lowers the warfarin requirement by 25% to 50%. We recommend a 25% prophylactic reduction of warfarin dosage and weekly measurements of PT for one month when amiodarone therapy is initiated.

(Arch Intern Med 1988;148:1779-1781)

Author Affiliations
From the Section of Cardiovascular Diseases, Department of Medicine, Sinai Hospital of Detroit, and Wayne State University, Detroit.

Footnotes
Accepted for publication April 19, 1988.

Presented in part as a poster presentation at the 35th Annual Scientific Session of the American College of Cardiology, Atlanta, March 11, 1986.

Reprint requests to the Section of Cardiovascular Diseases, Department of Medicine, Sinai Hospital of Detroit, 6767 W Outer Dr, Detroit, MI 48235 (Dr Kerin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Characteristics of the amiodarone-warfarin interaction during long-term follow-up
Lu et al.
Am J Health Syst Pharm 2008;65:947-952.
ABSTRACT | FULL TEXT  

Possible Amiodarone Warfarin Interaction: A Reemphasis on a Potentially Dangerous Drug Drug Interaction
Plakogiannis and Ginzburg
Journal of Pharmacy Practice 2007;20:469-473.
ABSTRACT  

Assessment of an Age-Adjusted Warfarin Initiation Protocol
Roberts et al.
The Annals of Pharmacotherapy 2003;37:799-803.
ABSTRACT | FULL TEXT  

Clinical Observations With the Amiodarone/Warfarin Interaction : Dosing Relationships With Long-term Therapy
Sanoski and Bauman
Chest 2002;121:19-23.
ABSTRACT | FULL TEXT  

Role of Desethylamiodarone in the Anticoagulant Effect of Concurrent Amiodarone and Warfarin Therapy
Naganuma et al.
J CARDIOVASC PHARMACOL THER 2001;6:363-367.
ABSTRACT  

Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?
Li and Hohnloser
J CARDIOVASC PHARMACOL THER 1998;3:185-194.
ABSTRACT